Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m. ET.